This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Hydroxyurea

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Hydroxycarbamide (former British Approved Name hydroxyurea) is a ribonucleoside reductase inhibitor that suppresses cell division. Its main use is in the treatment of chronic myeloid leukaemia but it also has a prophylactic role in the management of sickle cell anaemia.

Hydroxycarbamide has replaced the alkylating agents busulphan and chlorambucil as the most commonly used cytotoxic therapy in polycythaemia rubra vera in the UK.

Hydroxycarbamide is not thought to increase the long-term risk of leukaemic transformation, unlike alkylating agents and radio-phosphorous. Nausea and skin reactions are the most common toxic effects.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.